Point-of-Care Infectious Disease Diagnostics/Testing Market Worth $1.9 Billion by 2025: Grand View Research, Inc.

SAN FRANCISCO, September 6, 2017 /PRNewswire/ --

The global point-of-care infectious disease diagnostics/testing market is expected to reach USD 1.90 billion by 2025, according to a new report by Grand View Research, Inc. The emerging trend of patient-centric services coupled with escalating incidence rates of complicated infectious disorders is expected to upsurge the demand for portable and accurate detection devices, thus resulting in market growth. The potential in these devices to enable rapid detection of infectious diseases is attributive for the estimated market.

     (Logo: http://photos.prnewswire.com/prnh/20160524/371361LOGO )

Moreover, revolutionizing patient care brought about by these devices is responsible for the rising demand for decentralized testing settings. Rise in the investments for R&D and development of new products is expected to spur progress in this market through to 2025.

For instance, development of a new 'lab-on-a-disc' technology developed by an EU project research team aids in the diagnosis of different infectious diseases including malaria. It enables faster diagnosis as a consequence of implementation of point-of-care treatment. This allows precise drugs administration thus influencing adoption rate.

Browse full research report with TOC on "Point-of-Care Infectious Disease Diagnostics/Testing Market Analysis By Disease (HIV POC, HBV POC, Influenza/Flu POC, TB & drug-resistant TB POC), By End-use, And Segment Forecasts, 2014 - 2025" at: http://www.grandviewresearch.com/industry-analysis/point-of-care-infectious-disease-diagnostics-testing-market

Further key findings from the report suggest: 

• HIV POC is estimated to account for the largest share owing to the rising incidence of this disease
• Advances in the bio sensing technology for the early detection with sensitivity is expected to fuel revenue generation in the coming years
• Moreover, companies are engaged in embracing a quality management approach for the introduction of novel tests for HIV diagnosis
• TB and drug resistant TB is anticipated to witness lucrative demand in the coming years as a result of rise in the incidence rate of drug resistance TB
• Demand for the development of inexpensive, rapid, simple, and accurate tests that are able to detect multiple biomarkers simultaneously is expected to boost progress
• Implementation of fully or partially integrated nano/microscale technologies in developing DR-TB diagnostic devices is anticipated to fuel progress in the segment
• Clinics accounted for the largest revenue share owing to the higher usage of rapid testing kits in clinics
• North America dominates the space with adequate administration support, well-established healthcare framework, and extensive research & technology upgradation
• Asia Pacific region is expected to showcase the fastest growth over the forecast period due to rising incidence and prevalence rates of infectious diseases with suitable government support
• The major players in the sector include Siemens Healthineers, Trivitron Healthcare, F. Hoffmann-La Roche Ltd, Alere, Quest Diagnostics, Inc., BD & Company, Chembio Diagnostics Inc., Trinity Biotech, Cardinal Health, Bio-Rad Labs Inc., bioMérieux SA, Thermo Fisher Scientific Inc., Sight Diagnostics Ltd., Gene POC, Ortho-Clinical Diagnostics, and OJ-Bio Ltd.
• Companies are entering into collaborations with academic institutions, private, and public entities to enhance their market share

Browse related reports by Grand View Research: 

• Diabetes Treatment Market - http://www.grandviewresearch.com/industry-analysis/diabetes-treatment-market
  
• Genetic Disease Diagnostic Market - http://www.grandviewresearch.com/industry-analysis/genetic-disease-diagnostic-market
  
• Asthma & COPD Market - http://www.grandviewresearch.com/industry-analysis/asthma-and-copd-market
  
• Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market -  http://www.grandviewresearch.com/industry-analysis/pharmacogenomics-technology-theranostics-companion-diagnostics-cdx-market

Grand View Research has segmented the point-of-care infectious disease diagnostics/testing market on the basis of disease, end-use, and region: 

• Disease Outlook (Revenue, USD Million; 2014-2025) 
  • HIV POC
  • Clostridium difficile POC
  • HBV POC
  • Pneumonia or Streptococcus associated infections
  • Respiratory syncytial virus (RSV) POC
  • HPV POC
  • Influenza/Flu POC
  • HCV POC
  • MRSA POC
  • TB and drug-resistant TB POC
  • HSV (Herpes Simplex Virus) POC
  • Other infectious disease POC
• End-Use Outlook (Revenue, USD Million; 2014-2025) 
  • Hospitals
  • Clinics
  • Home
  • Assisted Living Healthcare Facilities
  • Laboratories
  • Others
• Regional Outlook (Revenue, USD Million; 2014-2025) 
  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • UK
  • Asia Pacific
    • Japan
    • China
  • Latin America
    • Brazil
  • Middle East and Africa (MEA)
    • South Africa

Read Our Blog By Grand View Research: http://www.grandviewresearch.com/blogs/healthcare

About Grand View Research 

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: +1-415-349-0058
Toll Free: 1-888-202-9519
Email: [email protected]

Web: http://www.grandviewresearch.com

SOURCE Grand View Research, Inc.